Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18738385 | STRAIN OF SELENIUM-ENRICHED LACTIPLANTIBACILLUS PLANTARUM KD-2 AND APPLICATIONS IN PREPARING FERMENTED GOAT MILK AND GOAT MILK POWDER | June 2024 | April 2025 | Allow | 10 | 1 | 1 | No | No |
| 18663247 | CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USE | May 2024 | May 2025 | Allow | 12 | 1 | 1 | No | No |
| 18609152 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS | March 2024 | May 2025 | Allow | 14 | 1 | 0 | No | No |
| 18600195 | AGENT FOR INDUCING INTERFERON PRODUCTION CONTAINING LACTIC ACID BACTERIA | March 2024 | August 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18591306 | Prevotella Copri Compositions | February 2024 | April 2025 | Allow | 13 | 1 | 0 | No | No |
| 18584070 | METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASES | February 2024 | May 2025 | Allow | 15 | 2 | 0 | No | No |
| 18443739 | RECOMBINANT VACCINE AGAINST HELMINTHS IN PICHIA PASTORIS AND METHODS FOR PRODUCING AND PURIFYING PROTEINS FOR USE AS VACCINES AGAINST HELMINTHS | February 2024 | December 2025 | Abandon | 22 | 2 | 0 | Yes | No |
| 18407367 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF | January 2024 | February 2025 | Allow | 14 | 1 | 1 | No | No |
| 18392708 | COMPOSITION FOR SUPPRESSING OR IMPROVING EYE FATIGUE | December 2023 | June 2025 | Allow | 18 | 2 | 1 | No | No |
| 18392435 | LYOPHILIZED COMPOSITIONS COMPRISING FECAL MICROBE-BASED THERAPEUTIC AGENTS AND METHODS FOR MAKING AND USING SAME | December 2023 | October 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18470301 | SYNTHETIC PLASMODIUM ANTIGENS, COMPOSITIONS, AND USES THEREOF | September 2023 | March 2025 | Allow | 18 | 2 | 1 | No | No |
| 18280907 | METHOD AND KIT FOR IDENTIFYING ANTIMICROBIAL AGENTS AND EFFECTIVE CONCENTRATIONS THEREOF | September 2023 | December 2025 | Allow | 27 | 2 | 0 | No | No |
| 18235157 | GANGLIOSIDE GM3-CONTAINING NANOPARTICLES AS IMMUNOMODULATORS | August 2023 | August 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18364104 | NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE | August 2023 | September 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18361084 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS | July 2023 | August 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18361724 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | July 2023 | November 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18271259 | JOINT FUNCTION-IMPROVING COMPOSITION | July 2023 | January 2026 | Allow | 31 | 1 | 1 | No | No |
| 18259441 | NOVEL STRAIN OF Bifidobacterium animalis subsp. lactis HEM20-01 AND COMPOSITION FOR treating depression, COMPRISING the same OR its culture fluid | June 2023 | December 2025 | Allow | 29 | 1 | 0 | Yes | No |
| 18328162 | MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES | June 2023 | January 2025 | Allow | 20 | 1 | 1 | No | No |
| 18326446 | METHOD AND SYSTEM FOR PRODUCING EUGLENA BIOMASS WITH CONTROLLED BIOMASS COMPOSITIONS | May 2023 | February 2026 | Abandon | 32 | 0 | 1 | No | No |
| 18254176 | STRAIN FOR DEGRADING DEOXYNIVALENOL AND USE THEREOF | May 2023 | November 2025 | Allow | 30 | 1 | 0 | No | No |
| 18038010 | Rhodococcus qingshengii bacterial strain that degrades imazethapyr and stimulates crop growth | May 2023 | January 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18300049 | MICROBIOTA COMPOSITION, AS A MARKER OF RESPONSIVENESS TO ANTI-PD1/PD-L1/PD-L2 ANTIBODIES AND USE OF MICROBIAL MODULATORS FOR IMPROVING THE EFFICACY OF AN ANTI-PD1/PD-L1/PD-L2 AB-BASED TREATMENT | April 2023 | July 2024 | Allow | 15 | 1 | 1 | No | No |
| 18131560 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | April 2023 | September 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18193151 | INSECTICIDAL POLYPEPTIDES HAVING IMPROVED ACTIVITY SPECTRUM AND USES THEREOF | March 2023 | April 2025 | Allow | 24 | 2 | 1 | No | No |
| 18189051 | COMPOSITIONS COMPRISING CelTOS IMMUNOGENS AND ANTIBODIES AND METHOD OF USE THEREOF | March 2023 | October 2025 | Allow | 31 | 1 | 1 | No | No |
| 18027621 | COMPOSITION CONTAINING FUNCTIONAL BLACK SOYBEAN POWDER BIOCONVERTED BY USING BACILLUS ENZYMES AS ACTIVE INGREDIENT, AND USE THEREOF | March 2023 | March 2026 | Abandon | 36 | 1 | 1 | No | No |
| 18027619 | DEVELOPMENT OF BIOCONVERSION PROCESS FOR FUNCTIONAL BLACK SOYBEAN POWDER BIOCONVERTED USING ENZYME GROUP DERIVED FROM BACILLUS BACTERIA AND USE THEREOF | March 2023 | March 2026 | Abandon | 36 | 1 | 1 | No | No |
| 18183544 | Use of Lactobacillus paracasei GMNL-346 for anti-oral cancer treatment and thereof | March 2023 | September 2025 | Allow | 30 | 2 | 0 | No | No |
| 18173288 | BIOMARKERS AND IMMUNOGENIC COMPOSITIONS FOR FILARIAL PARASITES | February 2023 | January 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18090413 | FECAL FUNGOME AND THERAPEUTIC EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION | December 2022 | June 2025 | Allow | 29 | 2 | 0 | No | No |
| 17993329 | COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASES | November 2022 | May 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17993310 | Pet Food Compositions Including Probiotics and Methods of Manufacture and Use Thereof | November 2022 | June 2025 | Allow | 30 | 2 | 0 | No | No |
| 18056151 | Compositions and Methods for Generating Tick Immunity | November 2022 | September 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17986424 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS | November 2022 | June 2023 | Allow | 7 | 1 | 0 | No | No |
| 17924064 | Methods for Verification of Drug Levels Using Dried Blood Samples | November 2022 | March 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 18047477 | Novel Bifidobacterium Genus Bacterium | October 2022 | June 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 18046751 | ANTIBODIES TO BOTULINUM NEUROTOXINS | October 2022 | January 2026 | Abandon | 39 | 4 | 1 | No | No |
| 17771638 | Holistic and Environmentally-Friendly Systems for Crop, Soil, Water and Livestock Management | September 2022 | February 2026 | Abandon | 46 | 0 | 1 | No | No |
| 17995004 | NOVEL USE OF BCG IMMUNOGENIC FORMULATION EXPRESSING A HUMAN RESPIRATORY SYNCYTIAL VIRUS PROTEIN AGAINST bRSV IN CATTLE | September 2022 | November 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17931280 | Polypeptides having Protease Activity and Polynucleotides Encoding Same | September 2022 | October 2025 | Allow | 37 | 1 | 1 | No | No |
| 17930219 | IMMUNOTHERAPIES EMPLOYING SELF-ASSEMBLING VACCINES | September 2022 | February 2026 | Abandon | 41 | 3 | 1 | No | No |
| 17802231 | METHOD FOR EVALUATING BIOFILM FORMATION, AND INVERTEBRATE FOR USE IN EVALUATING BIOFILM FORMATION | August 2022 | December 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17821730 | CLOSTRIDIUM DIFFICILE ANTIGENS | August 2022 | August 2025 | Allow | 36 | 2 | 1 | No | No |
| 17881131 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS | August 2022 | October 2022 | Allow | 2 | 0 | 0 | No | No |
| 17815221 | VACCINE COMPOSITION AGAINST STREPTOCOCCUS SUIS INFECTION | July 2022 | February 2026 | Allow | 43 | 5 | 0 | Yes | No |
| 17862269 | TREATMENTS OF CANCER USING NITROUS OXIDE AND BOTULINIUM TOXIN | July 2022 | January 2025 | Allow | 30 | 2 | 1 | Yes | No |
| 17861587 | DERMAL FILLER | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17838698 | COMPOSITION FOR SUPPRESSING OR IMPROVING EYE FATIGUE | June 2022 | September 2023 | Allow | 15 | 2 | 0 | Yes | No |
| 17783725 | S. AUREUS ANTIGENS AND COMPOSITIONS THEREOF | June 2022 | November 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17833962 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | June 2022 | November 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17834865 | PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASE | June 2022 | May 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17774374 | RECOMBINANT YEAST CAPABLE OF PRODUCING CAFFEIC ACID AND/OR FERULIC ACID | May 2022 | January 2026 | Allow | 45 | 2 | 1 | No | No |
| 17731106 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS | April 2022 | July 2022 | Allow | 3 | 0 | 0 | No | No |
| 17711257 | Strain of Lactobacillus rhamnosus and Application thereof in Inhibiting Helicobacter pylori | April 2022 | January 2025 | Allow | 34 | 1 | 1 | No | No |
| 17764878 | CLOSTRODIOIDES DIFFICILE TREATMENT | March 2022 | November 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17764498 | PSEUDOMONAS ISOLATES AND USES THEREOF | March 2022 | March 2025 | Allow | 36 | 1 | 0 | No | No |
| 17703790 | IMMUNOGENIC FUSION PROTEIN | March 2022 | August 2024 | Allow | 29 | 2 | 1 | No | No |
| 17694181 | BENEFICIAL BACTERIA AND SECRETORY IMMUNOGLOBULIN A | March 2022 | January 2026 | Abandon | 46 | 0 | 1 | No | No |
| 17692333 | TOXOPLASMA GONDII VACCINES AND THEIR USE | March 2022 | January 2024 | Allow | 22 | 1 | 1 | No | No |
| 17641315 | ANTIGEN BINDING PROTEIN AND ASSAYS | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17686606 | VACCINE COMPOSITION COMPRISING RECOMBINANT PROTEIN OF STAPHYLOCOCCUS AUREUS ATTENUATED ENTEROTOXIN AND CYTOTOXIN | March 2022 | March 2026 | Allow | 48 | 2 | 1 | No | No |
| 17638190 | FISH SKIN MICROBIOME | February 2022 | January 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17638321 | METHODS OF INCREASING VACCINE EFFICACY | February 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17636743 | IMMUNOLOGICALLY ACTIVE FRAGMENTS OF TOXOPLASMA GONDII | February 2022 | August 2024 | Allow | 30 | 3 | 1 | No | No |
| 17651033 | COMPOSITIONS AND METHODS FOR PROMOTING NITRIC OXIDE PRODUCTION THROUGH AN ORAL DELIVERY SYSTEM | February 2022 | January 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17633791 | TEST SYSTEM FOR RECOGNIZING LEGIONELLAE | February 2022 | January 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17629673 | ANTI-NEOPLASTIC COMBINED PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | January 2022 | January 2026 | Abandon | 48 | 2 | 1 | No | No |
| 17629269 | IN VITRO METHOD FOR DISCRIMINATING LATENT FROM ACTIVE TUBERCULOSIS | January 2022 | January 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17571079 | NOVEL IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF | January 2022 | March 2025 | Allow | 38 | 2 | 1 | No | No |
| 17597051 | COMPOSITIONS COMPRISING SECRETORY IgA AND PROBIOTICS | December 2021 | April 2025 | Allow | 40 | 2 | 1 | No | No |
| 17622177 | NOVEL PROBIOTIC COMPOSITION FOR REGULATION OF INTESTINAL IMMUNITY | December 2021 | November 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17558418 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | December 2021 | August 2023 | Abandon | 20 | 2 | 0 | No | No |
| 17554354 | PNEUMOCOCCAL CONJUGATE VACCINE FORMULATIONS | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17548904 | AGENT FOR INDUCING INTERFERON PRODUCTION CONTAINING LACTIC ACID BACTERIA | December 2021 | December 2023 | Allow | 24 | 1 | 1 | No | No |
| 17545148 | PROBIOTIC BIFIDOBACTERIUM STRAIN | December 2021 | September 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17541546 | DERMAL FILLER | December 2021 | December 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17533320 | ANTI-INFLAMMATORY COMPOUNDS AND METHODS OF USE | November 2021 | August 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17532034 | Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa | November 2021 | November 2023 | Allow | 24 | 1 | 0 | No | No |
| 17608230 | CONJUGATE PRODUCTION | November 2021 | October 2025 | Allow | 48 | 2 | 1 | No | No |
| 17515985 | METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASES | November 2021 | June 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17502259 | Penicillium oxalicum SDF-25 strain and application thereof | October 2021 | March 2025 | Allow | 41 | 1 | 1 | No | No |
| 17499004 | IMMUNOGENIC COMPOSITION, USE AND METHOD OF TREATMENT | October 2021 | November 2025 | Abandon | 49 | 1 | 1 | Yes | No |
| 17497157 | ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOF | October 2021 | April 2025 | Abandon | 42 | 3 | 1 | No | No |
| 17491889 | COMBINATIONS OF ANTI-STAPHYLOCOCCUS AUREUS ANTIBODIES | October 2021 | January 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17483162 | ANTIBODY DIRECTED AGAINST S. AUREUS CLUMPING FACTOR A (ClfA) | September 2021 | December 2023 | Allow | 27 | 1 | 1 | No | No |
| 17459715 | HELICOBACTER THERAPEUTIC | August 2021 | July 2023 | Allow | 22 | 1 | 0 | No | No |
| 17430117 | COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN | August 2021 | June 2025 | Allow | 47 | 2 | 1 | No | No |
| 17377475 | ROS KINASE IN LUNG CANCER | July 2021 | February 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17253798 | Vaccine Used For Preventing Toxoplasma Gondii Infection And Preparation Method Therefor | July 2021 | September 2022 | Allow | 21 | 2 | 1 | No | No |
| 17309996 | NANOVESICLES DERIVED FROM BACTERIA OF GENUS DEINOCOCCUS, AND USE THEREOF | July 2021 | January 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17368396 | COMPOSITION AND METHODS FOR TREATING CANCER AND IMMUNE DISORDERS USING VEILLONELLA BACTERIA | July 2021 | December 2023 | Allow | 29 | 1 | 1 | No | No |
| 17367812 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF | July 2021 | September 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17346362 | MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES | June 2021 | July 2023 | Allow | 25 | 1 | 1 | No | No |
| 17331536 | VACCINE FOR IMMUNOCOMPROMISED HOSTS | May 2021 | July 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17324606 | Rapid Analysis of Cyanobacterial Toxins | May 2021 | November 2022 | Allow | 17 | 0 | 0 | No | No |
| 17321719 | CLOSTRIDIUM DIFFICILE MULTI-COMPONENT VACCINE | May 2021 | October 2025 | Abandon | 53 | 1 | 2 | No | No |
| 17245584 | Compositions, Methods, and Systems for Detecting Methicillin-Resistant Staphylococcus Aureus | April 2021 | January 2026 | Allow | 57 | 3 | 1 | Yes | No |
| 17243455 | NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE | April 2021 | May 2023 | Allow | 25 | 1 | 1 | No | No |
| 17241494 | COMPOSITIONS AND METHODS FOR TREATING SECONDARY TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIUM INFECTIONS | April 2021 | July 2024 | Abandon | 39 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ZEMAN, ROBERT A.
With a 42.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ZEMAN, ROBERT A works in Art Unit 1645 and has examined 924 patent applications in our dataset. With an allowance rate of 49.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner ZEMAN, ROBERT A's allowance rate of 49.7% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ZEMAN, ROBERT A receive 2.33 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ZEMAN, ROBERT A is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +30.0% benefit to allowance rate for applications examined by ZEMAN, ROBERT A. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.9% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 36.0% of cases where such amendments are filed. This entry rate is in the 54% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 41.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 39% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 74.7% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 71.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 69.0% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.8% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.7% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.